Biotech | March 31, 2022
BioVaxys expands cancer vaccine platform
BVX-0922 to target colorectal cancer under investigator-sponsored IND
BVX-0922 to target colorectal cancer under investigator-sponsored IND
The Drug Registry intends to create a nationally recognized source of information on various systems of medicine in the country
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding cardiovascular services and timely, efficacious study outcomes.
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Dupixent peak sales ambition raised to more than €13 billion
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
Subscribe To Our Newsletter & Stay Updated
